Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Efficacy and safety of savolitinib in Chinese patients with locally advanced or metastatic MET exon 14-mutated non-small cell lung cancer: final results of a confirmatory Phase 3b study.
Journal: The Lancet regional health. Western Pacific
Published: October 30, 2025
Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study.
Fruquintinib plus sintilimab in advanced cervical cancer: an open-label, multicentre, phase 2 study.
Journal: Communications medicine
Published: September 18, 2025
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trial.
Journal: Nature communications
Published: May 19, 2025
Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study.
Journal: EClinicalMedicine
Published: March 29, 2025
Safety of fruquintinib in Chinese patients with colorectal cancer: an age subgroup analysis from a phase IV real-world clinical practice study.
Journal: Therapeutic advances in medical oncology
Published: March 10, 2025
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p).
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 07, 2025
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Trial.
Journal: Targeted oncology
Published: December 03, 2024
HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study.
Journal: Med (New York, N.Y.)
Published: August 07, 2024
Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study.
Journal: The Lancet. Haematology
Published: August 01, 2024
Efficacy and safety of surufatinib plus toripalimab in treatment-naive, PD-L1-positive, advanced or metastatic non-small-cell lung cancer and previously treated small-cell lung cancer: an open-label, single-arm, multicenter, multi-cohort phase II trial.
Journal: Cancer immunology, immunotherapy : CII
Published: July 03, 2024
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study.
Journal: The Lancet. Respiratory medicine
Published: April 03, 2024
Last Updated: 09/26/2026